Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 5/2011

01-10-2011 | Short Research Report

The clinical pharmacist’s contributions within the multidisciplinary patient care team of an intern nephrology ward

Authors: Gunar Stemer, Rosa Lemmens-Gruber

Published in: International Journal of Clinical Pharmacy | Issue 5/2011

Login to get access

Abstract

Objective To describe and evaluate newly implemented clinical pharmacy services and ward round participation on a specialized nephrology ward in a large tertiary care hospital. Method All issues addressed by the clinical pharmacist were systematically collected, and the contributions were classified by type. Where applicable, physicians’ acceptance rates were recorded. The drugs most commonly affected by the clinical pharmacist’s contributions are described. Results A total of 158 clinical pharmacist’s contributions were recorded. Approximately 90% (n = 104) of applicable suggestions (117 out of 158; 74%) were accepted by the treating physicians. Most issues were discussed with physicians (85%); the remaining issues were discussed with nurses and medical students. Antimicrobials, drugs affecting the alimentary system and metabolism, and cardiovascular drugs were among the most commonly affected drugs. Issues concerning dosage and drug-therapy selection were common. The clinical pharmacist was also involved in developing dosing guidelines and performing literature searches. Conclusion The observed effects of a newly implemented clinical pharmacy service on an internal nephrology ward are encouraging; acceptance rates of suggestions and the multidisciplinary appreciation of clinical pharmacy services are high.
Literature
1.
go back to reference American College of Clinical Pharmacy. The definition of clinical pharmacy. Pharmacotherapy. 2008;28(6):816–7. American College of Clinical Pharmacy. The definition of clinical pharmacy. Pharmacotherapy. 2008;28(6):816–7.
2.
go back to reference Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med. 1995;155(18):1949–56.PubMedCrossRef Johnson JA, Bootman JL. Drug-related morbidity and mortality. A cost-of-illness model. Arch Intern Med. 1995;155(18):1949–56.PubMedCrossRef
3.
go back to reference Krahenbuhl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krahenbuhl S. Drug-related problems in hospitals: a review of the recent literature. Drug Saf. 2007;30(5):379–407.PubMedCrossRef Krahenbuhl-Melcher A, Schlienger R, Lampert M, Haschke M, Drewe J, Krahenbuhl S. Drug-related problems in hospitals: a review of the recent literature. Drug Saf. 2007;30(5):379–407.PubMedCrossRef
4.
go back to reference Viktil KK, Blix HS. The impact of clinical pharmacists on drug-related problems and clinical outcomes. Basic Clin Pharmacol Toxicol. 2008;102(3):275–80.PubMedCrossRef Viktil KK, Blix HS. The impact of clinical pharmacists on drug-related problems and clinical outcomes. Basic Clin Pharmacol Toxicol. 2008;102(3):275–80.PubMedCrossRef
5.
go back to reference Kucukarslan SN, Peters M, Mlynarek M, Nafziger DA. Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units. Arch Intern Med. 2003;163(17):2014–8.PubMedCrossRef Kucukarslan SN, Peters M, Mlynarek M, Nafziger DA. Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units. Arch Intern Med. 2003;163(17):2014–8.PubMedCrossRef
6.
go back to reference Manley HJ, Carroll CA. The clinical and economic impact of pharmaceutical care in end-stage renal disease patients. Semin Dial. 2002;15(1):45–9.PubMedCrossRef Manley HJ, Carroll CA. The clinical and economic impact of pharmaceutical care in end-stage renal disease patients. Semin Dial. 2002;15(1):45–9.PubMedCrossRef
7.
go back to reference Stemer G, Lemmens-Gruber R. Clinical pharmacy services and solid organ transplantation: a literature review. Pharm World Sci. 2010;32(1):7–18.PubMedCrossRef Stemer G, Lemmens-Gruber R. Clinical pharmacy services and solid organ transplantation: a literature review. Pharm World Sci. 2010;32(1):7–18.PubMedCrossRef
8.
go back to reference Manley HJ, Cannella CA, Bailie GR, St Peter WL. Medication-related problems in ambulatory hemodialysis patients: a pooled analysis. Am J Kidney Dis. 2005;46(4):669–80.PubMedCrossRef Manley HJ, Cannella CA, Bailie GR, St Peter WL. Medication-related problems in ambulatory hemodialysis patients: a pooled analysis. Am J Kidney Dis. 2005;46(4):669–80.PubMedCrossRef
9.
go back to reference Schuhmacher C, Amann S. Drug information from the hospital pharmacy [German]. Krankenhauspharmazie. 2009;30(3):119–26. Schuhmacher C, Amann S. Drug information from the hospital pharmacy [German]. Krankenhauspharmazie. 2009;30(3):119–26.
11.
go back to reference Surugue J, Vulto AG. Workforce of EU hospitals and pharmacy services: a direct patient safety issue. Eur J Hosp Pharm Pract. 2006;12:3. Surugue J, Vulto AG. Workforce of EU hospitals and pharmacy services: a direct patient safety issue. Eur J Hosp Pharm Pract. 2006;12:3.
Metadata
Title
The clinical pharmacist’s contributions within the multidisciplinary patient care team of an intern nephrology ward
Authors
Gunar Stemer
Rosa Lemmens-Gruber
Publication date
01-10-2011
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 5/2011
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-011-9548-4

Other articles of this Issue 5/2011

International Journal of Clinical Pharmacy 5/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.